CTKB
Cytek Biosciences·NASDAQ
--
--(--)
--
--(--)
3.72 / 10
Netural
Fund-flow data indicate a good score of 7.44/10, with net inflows in the overall, block, small, medium, large, and extra-large categories, although the overall trend is negative. This mixed signal implies that while institutional money is accumulating, it is doing so in a measured, possibly defensive manner. Analyst coverage is sparse—only one active analyst with a Strong Buy rating—limiting the breadth of professional conviction. The sentiment is Neutral, aligning with the overall investment recommendation.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-08
InstitutionTD Cowen
Times predicted1
Historical Win Rate0.0%
What is the analyst consensus for CTKB?
- CTKB holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.72/10 (Netural).
